Hongyi Tan

Using physiologically based pharmacokinetic modelling to optimize repaglinide and irbesartan dosing in Chinese population with SLCO1B1 polymorphism

Aim The first aim of this study was to develop physiologically based pharmacokinetic (PBPK) models for irbesartan (IRB) and repaglinide (REP) and then apply the REP/IRB PBPK model to describe the drug–drug interaction (DDI) of REP and IRB in the population with SLCO1B1 c.521 T &g...